

Sample content

Chronic Obstructive Pulmonary Disease

Disease Landscape & Forecast

Published: October 2024

About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?



What is the current treatment landscape?



What products are in development, and what is their launch potential and future positioning?



What is the market outlook of sales and patient share for the next 10 years?



What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?



What unmet needs and opportunities exist?

Methodology and scope


Market forecast

- **Forecast:** Annualized drug-level sales and patient share of key COPD therapies from 2023-2033, segmented by brands / generics.
- **Epidemiology:** Diagnosed and drug-treated prevalent cases of COPD by country.
- **Market segmentations:** Mild / moderate and severe / very severe.
- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Interviews with 25 thought-leading pulmonologists across the G7.
- Data and insights leveraged from 210 physician surveys conducted by Clarivate in COPD to model current and future market dynamics.

Geography




Key therapies covered

Phase 3	• Mepolizumab (GSK) • Benralizumab (AstraZeneca) • Itepekimab (Sanofi / Regeneron) • Tozorakimab (AstraZeneca) • Astegolimab (Roche)
Marketed	• Trelegy (GSK) • Trimbrow (Chiesi) • Breztri / Trixeo (AstraZeneca) • Ensifentrine (Verona) • Dupixent (Sanofi / Regeneron) • Albuterol / salbutamol (various)

Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
 - Key takeaways
 - Market drivers and constraints
 - Drug class-specific trends
4. **Disease Context**
5. **Epidemiology**
 - Key takeaways
 - Total prevalent cases of COPD
 - Total GOLD-defined prevalent cases
 - Spirometric-negative prevalent cases
 - Diagnosed prevalent cases of COPD
 - Diagnosed prevalent cases of COPD by severity
 - Drug-treated prevalent cases of COPD
- Eosinophilic COPD
- Acute exacerbations of COPD
6. **Current Treatment**
 - Key takeaways
 - Treatment for COPD
 - Key current therapies
7. **Emerging Therapies**
 - Key takeaways
 - Key emerging therapies
 - Unmet need in COPD
8. **Drug Pipeline** (*powered by Cortellis*)
9. **Appendix**




Report format

-  **In-depth written analyses** available on Clarivate's Insights Platform or as a PDF download
-  Succinct **Executive Summary** deck
-  **Market Forecast Assumptions** (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)
-  **Market Forecast Dashboard** (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

Sample content

Question answered


What are the expected sales of key drugs used to treat COPD in the G7 markets over the next 10 years?



Sample content

Question answered

What is the current treatment paradigm in COPD?



Sample content

Question answered

When are the key novel therapies expected to launch for the COPD market over the next 10 years?


Forecast market authorization dates of key emerging therapies for the treatment of COPD: 2023-2033

Drug	United States	Europe	Japan
Ensifentrine			
Dupilumab			
Mepolizumab			
Benralizumab			
Itepekimab			
Tozorakimab			

Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?



Sample content

Question answered

What is the expected number of drug-treated patients with COPD in the G7 over the next 10 years?

G7	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Total Chronic Obstructive Pulmonary Disease											
Diagnosed Population	18,875,000	19,079,800	19,295,000	19,520,800	19,757,100	19,993,900	20,231,200	20,469,000	20,707,300	20,946,000	21,185,100
Percentage Drug-Treated	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
Drug-Treated Population	14,156,250	14,279,850	14,401,250	14,530,600	14,657,550	14,782,425	14,905,400	15,026,250	15,145,000	15,261,750	15,376,575
Mild to Moderate COPD											
Diagnosed Population	18,875,000	19,079,800	19,295,000	19,520,800	19,757,100	19,993,900	20,231,200	20,469,000	20,707,300	20,946,000	21,185,100
Percentage Drug-Treated	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
Drug-Treated Population	14,156,250	14,279,850	14,401,250	14,530,600	14,657,550	14,782,425	14,905,400	15,026,250	15,145,000	15,261,750	15,376,575
Severe to Very Severe COPD											
Diagnosed Population	5,871,000	5,896,800	5,922,800	5,948,900	5,975,100	6,001,300	6,027,600	6,053,900	6,080,200	6,106,500	6,132,800
Percentage Drug-Treated	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%
Drug-Treated Population	4,696,800	4,717,440	4,738,240	4,759,120	4,780,080	4,799,040	4,817,880	4,836,600	4,855,300	4,873,900	4,892,480



About Clarivate

Disease Intelligence and Analytics

Disease intelligence you can trust



Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:

clarivate.com/products/biopharma/portfolio-strategy-business-development



Think forward™

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.